Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235094 | 1.00 | USP2 (0.33) | USP2SLCO1B1 | |
| SCHEMBL2803990 | 1.00 | USP2 (0.33) | USP2SLCO1B1 | |
| SCHEMBL6012668 | 0.85 | — | — | |
| SCHEMBL8704747 | 0.80 | USP2 (0.35) | USP2SLCO1B1 | |
| SCHEMBL17202055 | 0.78 | TDP1 (0.38) | USP2SLCO1B1 | |
| Sulfuric Acid SCHEMBL3238445 | 0.78 | USP2 (0.53) | USP2SLCO1B1 | |
| Sulfuric Acid SCHEMBL2221135 | 0.78 | USP2 (0.53) | USP2SLCO1B1 | |
| SCHEMBL4486141 | 0.77 | — | — | |
| SCHEMBL28719903 | 0.77 | — | — | |
| SCHEMBL11598425 | 0.77 | USP2 (0.35) | USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081586-B1 | METHOD FOR MODIFYING SURFACE AND SURFACE MODIFIED ELASTIC BODY | SUMITOMO RUBBER IND (JP) | 2019-07-24 | — | — | EP | claimed |
| CN-107982548-A | Compartmentation method of nucleic acid conveying and combinations thereof and application | 全球生物疗法有限公司 | 2018-05-04 | — | — | CN | claimed |
| WO-2010022461-A1 | SULPHATED SUGARS TO INCREASE ACTIVITY OF SULPHATASES EN LYSOSOMAL STORAGE DISORDERS | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE (AU) | 2010-03-04 | — | — | WO | claimed |
| WO-2026105698-A1 | METHOD FOR PRODUCING COLLAGEN-CONTAINING STRUCTURE | ＴＯＰＰＡＮホールディングス株式会社 | 2026-05-21 | — | — | WO | disclosed |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | KOBAYASHI PHARMACEUTICAL CO LTD (JP) | 2026-05-07 | — | — | US | disclosed |
| US-20250388635-A1 | PROTEOGLYCAN PRODUCTION METHOD AND PROTEOGLYCAN | NAT UNIV CORP TOTTORI UNIV (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4520838-A1 | PROTEOGLYCAN PRODUCTION METHOD AND PROTEOGLYCAN | National University Corporation Tottori University (JP) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024232423-A1 | METHOD FOR MEASURING PROTEOGLYCAN | 一丸ファルコス株式会社 | 2024-11-14 | — | — | WO | disclosed |
| WO-2024172098-A1 | AGENT FOR REDUCING ENDOTOXIN IN PROTEOGLYCANS DERIVED FROM ANIMAL TISSUES, AND METHOD FOR PRODUCING PROTEOGLYCAN | 国立大学法人鳥取大学 | 2024-08-22 | — | — | WO | disclosed |
| WO-2024142827-A1 | PROTEOGLYCAN PRODUCTION METHOD AND PROTEOGLYCAN | 国立大学法人鳥取大学 | 2024-07-04 | — | — | WO | disclosed |
| CN-114204122-B | Lithium ion battery flame-retardant electrolyte and preparation method and application thereof | 华中科技大学 | 2024-03-19 | — | — | CN | disclosed |
| EP-1603578-A2 | CYSTITIS TREATMENT WITH HIGH DOSE CHONDROITIN SULFATE | Stellar International Inc. (CA) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005087943-A1 | TEMPORAL OR SPATIAL CHARACTERIZATION OF BIOSYNTHETIC EVENTS IN LIVING ORGANISMS BY ISOTOPIC FINGERPRINTING UNDER CONDITIONS OF IMPOSED ISOTOPIC GRADIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005025502-A2 | A METHOD FOR TREATING OR INHIBITING THE EFFECTS OF INJURIES OR DISEASES THAT RESULT IN NEURONAL DEGENERATION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004073584-A2 | CYSTITIS TREATMENT WITH HIGH DOSE CHONDROITIN SULFATE | STELLAR INTERNATIONAL INC. (CA) | 2004-09-02 | — | — | WO | disclosed |
| EP-1017405-A4 | THERAPEUTIC HEMOGLOBIN COMPOSITION HAVING ISOTROPICALLY INCREASED SIZE | BAXTER INT (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1192180-A1 | PRODUCT FROM STARFISH | KING'S COLLEGE LONDON (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000075183-A1 | PRODUCT FROM STARFISH | KING'S COLLEGE LONDON (GB) | 2000-12-14 | — | — | WO | disclosed |
| EP-1017405-A1 | THERAPEUTIC HEMOGLOBIN COMPOSITION HAVING ISOTROPICALLY INCREASED SIZE | BAXTER INTERNATIONAL INC. (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999003484-A1 | THERAPEUTIC HEMOGLOBIN COMPOSITION HAVING ISOTROPICALLY INCREASED SIZE | BAXTER INTERNATIONAL INC. (US) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | CSGALNACT1, CD44, HCAR1 | USP2 3880/4885SLCO1B1 1273/4885 |
| US-20250388635-A1 | PROTEOGLYCAN PRODUCTION METHOD AND PROTEOGLYCAN | COL2A1, MMP13, COL1A1 | USP2 2658/4885SLCO1B1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.